Successful switch to dabrafenib after vemurafenib-induced toxic epidermal necrolysis.
Service de Dermatologie, Centre Hospitalier Universitaire, 21000, Dijon, France. geraldine.jeudy@chu-dijon.fr.
G
G
Jeudy
Service de Dermatologie, Centre Hospitalier Universitaire, 21000, Dijon, France.
S
S
Dalac-Rat
Service de Dermatologie, Centre Hospitalier Universitaire, 21000, Dijon, France.
B
B
Bonniaud
Service de Dermatologie, Centre Hospitalier Universitaire, 21000, Dijon, France.
A
A
Hervieu
Service d'Anatomie Pathologique, Centre Hospitalier Universitaire, 21000, Dijon, France.
T
T
Petrella
Service de Dermatologie, Centre Hospitalier Universitaire, 21000, Dijon, France.
E
E
Collet
Service de Dermatologie, Centre Hospitalier Universitaire, 21000, Dijon, France.
P
P
Vabres
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D057915:Drug Substitution; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use*; D007211:Indoles / Q000009:adverse effects*; D008297:Male; D008545:Melanoma / Q000188:drug therapy; D008875:Middle Aged; D009362:Neoplasm Metastasis; D010091:Oximes / Q000627:therapeutic use*; D012878:Skin Neoplasms / Q000188:drug therapy; D013262:Stevens-Johnson Syndrome / Q000209:etiology*; D013449:Sulfonamides / Q000009:adverse effects*; D000077484:Vemurafenib
D000970:Antineoplastic Agents; D007093:Imidazoles; D007211:Indoles; D010091:Oximes; D013449:Sulfonamides; D000077484:Vemurafenib; C561627:dabrafenib